...
CLDXMID

Celldex Therapeutics, Inc.

HealthcareBiotechnology
$30.09
$0.01(-1.80%)
52W$14.40
$31.29
FinancialsValuationvs REGN
Updated Mar 2, 12:00 AM
RSI72
RS Rating78/99
Beta1.14
Volatility64%
F-Score3/9
Mkt Cap$2.0B
EMERGING TREND

Price Action

5Y Daily
50 DMA150 DMA200 DMA

Technical Summary

EMERGING TREND

Celldex Therapeutics, Inc. is attempting to emerge into an uptrend but lacks full moving average alignment. Relative strength is moderate (RS Rating: 78), indicating performance broadly in line with the market. Earnings contraction of 73% provides fundamental context to the price action. Investors should exercise caution due to high volatility (64% annualized), which requires wider risk management.

Relative Strength
78
out of 99
Average
Trend Score
3/4
Minervini Criteria
EMERGING TREND
Risk (Beta)
1.14
vs S&P 500
ABOVE MKT
52W Position
93%
from 52W low
Near High
Trend & Momentum Analysis

Trend Template (Minervini)

EMERGING TREND3/4 Criteria Met
CriterionValueStatus
Price > 50 SMA$25.70
50 SMA > 100 SMA$26.04
100 SMA > 150 SMA$25.24
150 SMA > 200 SMA$24.21

Price vs Moving Averages

PeriodValueSpreadSignal
20 SMA$24.94+20.63%ABOVE
50 SMA$25.70+17.07%ABOVE
100 SMA$26.04+15.54%ABOVE
150 SMA$25.24+19.21%ABOVE
200 SMA$24.21+24.29%ABOVE

Price Performance

1D-1.8%
1W+23.7%
1M+21.5%
3M+11.4%
6M+34.5%
YTD+11.4%
1Y+46.3%
3Y-11.1%
52-Week Trading Range93% from low
$30.09
52W Low$14.40
52W High$31.29

Technical Indicators

RSI (14)OVERBOUGHT
71.7
305070
VCP ScoreWARM
6/10
Base depth: 29.8%

Risk Profile

Beta
1.14
52W Vol
64%
ATR
$1.61
Max DD (1Y)
-29%

Volume Analysis

Today
30
50D Avg
547.1K
Vol Ratio
0.00x
Liquidity
MODERATE

Earnings Momentum

Q1'25-45%
$-0.81
Q2'25-57%
$-0.85
Q3'25-58%
$-1.01
Q4'25-73%
$-1.23
Fundamentals & Growth

Growth Trends

Compounded Sales Growth

10 Years:-12.15%
5 Years:-27.36%
3 Years:-13.98%
TTM:-78.63%

Compounded Profit Growth

10 Years:—
5 Years:—
3 Years:—
TTM:-59.18%

Stock Price CAGR

10 Years:-11.49%
5 Years:+1.31%
3 Years:-11.07%
1 Year:+46.28%

Return on Equity

10Y Avg:-41.1%
5Y Avg:-31.5%
3Y Avg:-35.0%
Last Year:-49.1%

Key Metrics

Market Cap$2.0B
Gross Margin1.0%
Net Margin-172.5%
Piotroski F-Score3/9

More CLDX Analysis

Full Financial AnalysisDCF & Intrinsic ValueTotal Return Calculator

Compare With

CLDX vs REGNREGNCNTAIMNMRXRX

Data Dictionary

RS Rating (Relative Strength)

Measures 12-month price performance vs all stocks. Rating of 78 meansCLDX outperformed 78% of all stocks. Scores >80 indicate market leaders.

Beta

Measures volatility vs S&P 500. Beta of 1.14 means 14% more volatile than market.

Piotroski F-Score

9-point financial strength score based on profitability, leverage, and efficiency. Score of 3/9. Scores 7-9 = strong, 4-6 average, 0-3 = weak.

VCP (Volatility Contraction Pattern)

Measures base formation quality. Higher scores indicate tighter consolidation near pivot points. Score of 6/10 with WARM status.

Frequently Asked Questions

Is CLDX in an uptrend right now?

CLDX has a trend score of 3/4 based on Minervini's Stage Analysis. Currently showing partial alignment - 3 of 4 trend criteria are met.

Is CLDX overbought or oversold?

CLDX's RSI (14) is 72. The stock is in overbought territory (RSI > 70), which may signal a pullback.

Is CLDX outperforming the market?

CLDX has a Relative Strength (RS) Rating of 78 out of 99. CLDX is performing about average compared to the market.

Where is CLDX in its 52-week range?

CLDX is trading at $30.09, which is 96% of its 52-week high ($31.29) and 93% above its 52-week low ($14.40).

How volatile is CLDX?

CLDX has a Beta of 1.14 and 52-week volatility of 64%. It's more volatile than the S&P 500 - expect bigger swings.